CTAG2 and prostate carcinoma: Previous analyses of published databases showed that 25%–50% of LAGE1 samples were expressed in melanoma tumors, non-small cell lung carcinomas, and head, bladder, neck, and prostate cancers, and so LAGE1 mRNA expression was found in 22 of 107 (21%) tumor tissues [68,69].